Stay updated on GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial page
- CheckyesterdayChange DetectedRecruitment status updated to No longer looking for participants, indicating enrollment has closed for this study. This update is logged under Revision: v3.6.0 on 2026-06-10.SummaryDifference1%

- Check9 days agoChange DetectedThe history page displays a new site revision label, v3.5.5, replacing the previous v3.5.4, indicating an underlying platform update.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedA new revision tag (v3.5.4) was added to the study history, replacing the previous v3.5.3 tag. This reflects an administrative update to the record history.SummaryDifference0.1%

- Check52 days agoChange DetectedThe page revision/version indicator was updated from v3.5.2 to v3.5.3 for the ClinicalTrials.gov record history interface.SummaryDifference0.1%

- Check59 days agoChange DetectedAdded Revision: v3.5.2 and removed Revision: v3.5.0 from the history page.SummaryDifference0.1%

- Check88 days agoChange DetectedThe page history now includes a new revision labeled v3.5.0 and removes the previous v3.4.3 entry.SummaryDifference0.1%

Stay in the know with updates to GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial page.